Target type: biologicalprocess
Any process that modulates the frequency, rate or extent of heart morphogenesis. [GOC:BHF]
Heart morphogenesis, the intricate process of shaping the heart from a simple tube into a complex, four-chambered organ, is tightly regulated by a complex interplay of genetic and environmental factors. This intricate orchestration involves precise control of cell proliferation, differentiation, migration, and apoptosis, ensuring proper development of the heart chambers, valves, and surrounding structures.
The process begins with the specification of the cardiac progenitor cells, which commit to a cardiac fate. This involves the expression of key transcription factors, including Nkx2.5, GATA4, and MEF2C, which regulate the expression of downstream target genes essential for heart development. These early events lay the foundation for subsequent heart morphogenesis, setting the stage for the formation of the heart tube.
As the heart tube forms, it undergoes a series of coordinated morphogenetic movements, including looping and chamber formation. This intricate choreography is driven by a combination of intrinsic cellular cues and external signals, such as retinoic acid and fibroblast growth factors. These signaling pathways act in concert to orchestrate the precise arrangement and differentiation of cardiac cells, ensuring the proper development of the heart chambers.
The heart tube elongates and folds into a characteristic S-shape, a process known as looping. This looping is critical for the proper positioning of the heart within the thorax and for the subsequent separation of the heart into distinct chambers. Simultaneously, the heart tube begins to divide into the four chambers: the atria and ventricles. This chamber formation involves the growth of septa, partitions that separate the atria from the ventricles and the left ventricle from the right ventricle.
Concurrently, the heart valves, which regulate blood flow through the heart, begin to develop. These valves form from endocardial cushions, specialized structures that originate from the inner lining of the heart. The endocardial cushions undergo a complex process of differentiation, proliferation, and apoptosis, ultimately forming the distinct valve leaflets.
Throughout this intricate process, various signaling pathways are activated, including the Wnt, TGFβ, and Notch pathways. These pathways play crucial roles in regulating cell proliferation, differentiation, migration, and apoptosis, all essential for the proper development of the heart. Moreover, extracellular matrix proteins, such as fibronectin and collagen, provide structural support and guidance for migrating cells.
Finally, the heart matures, with the development of the conduction system that regulates the electrical activity of the heart. This intricate network of specialized cells ensures that the heart beats rhythmically and effectively pumps blood throughout the body.
Disruptions in any of these intricate processes can lead to congenital heart defects, affecting the structure and function of the heart. These defects range from minor abnormalities to life-threatening conditions, emphasizing the critical importance of tight regulation of heart morphogenesis.
In summary, heart morphogenesis is a complex and highly orchestrated process involving the precise control of cell proliferation, differentiation, migration, and apoptosis. It is regulated by an intricate network of signaling pathways and transcription factors, ensuring the proper development of a functional, four-chambered heart.'
"
Protein | Definition | Taxonomy |
---|---|---|
Smoothened homolog | A protein smoothened that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q99835] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
cyclopamine | piperidines | glioma-associated oncogene inhibitor | |
pd 173955 | PD 173955: inhibits src family-selective tyrosine kinase; structure in first source | aryl sulfide; dichlorobenzene; methyl sulfide; pyridopyrimidine | tyrosine kinase inhibitor |
purmorphamine | purmorphamine : A member of the class of purines that is purine substituted at C-2 by a 1-naphthyloxy group, at C-4 by a 4-morpholinophenylamino group, and at N-9 by a cyclohexyl group. purmorphamine: structure in first source | aromatic ether; morpholines; purines; secondary amino compound | osteogenesis regulator; SMO receptor agonist |
cur 61414 | CUR 61414: inhibits the hedehog signaling pathway; structure in first source | ||
abt 869 | aromatic amine; indazoles; phenylureas | angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | |
lde225 | sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma. sonidegib: specific Smoothened/Smo antagonist | aminopyridine; aromatic ether; benzamides; biphenyls; morpholines; organofluorine compound; tertiary amino compound | antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist |
gdc 0449 | HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity | benzamides; monochlorobenzenes; pyridines; sulfone | antineoplastic agent; Hedgehog signaling pathway inhibitor; SMO receptor antagonist; teratogenic agent |
N-[[3-fluoro-4-[[2-(1-methyl-4-imidazolyl)-7-thieno[3,2-b]pyridinyl]oxy]anilino]-sulfanylidenemethyl]-2-phenylacetamide | thioureas | ||
ipi-926 | IPI-926: a semisynthetic derivative of cyclopamine that is a smoothened inhibitor with antineoplastic activity; structure in first source | piperidines | |
gsk 1363089 | GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first source | aromatic ether | |
tak-441 | TAK-441: structure in first source | ||
ly2940680 | |||
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea | BGJ-398 : A member of the class of phenylureas that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 2,6-dichloro-3,5-dimethoxyphenyl group, while the hydrogens attached to the other nitrogen are replaced by a methyl group and a 6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl group. It is a potent and selective fibroblast growth factor receptor inhibitor. infigratinib: structure in first source | aminopyrimidine; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; phenylureas | antineoplastic agent; fibroblast growth factor receptor antagonist |
cep-32496 | agerafenib: inhibitor of RAF family kinases; structure in first source | ||
pf-5274857 | 1-(4-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)piperazin-1-yl)-3-(methylsulfonyl)propan-1-one: a potent and selective Smoothened antagonist that penetrates the blood-brain barrier; structure in first source |